12:00 AM
May 28, 2012
 |  BC Week In Review  |  Company News  |  Deals

Almirall, Aslan deal

Almirall granted Aslan exclusive, worldwide rights to develop LAS186323, a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan will conduct and fund development through the...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >